[F110. Regulation 4 is amended as follows—U.K.
(a)in paragraph 1—
(i)omit sub-paragraph (b);
(ii)at the end, after “in accordance with” insert “paragraphs 1 and 3 respectively of”;
(b)after paragraph 1, insert—
“(1A) A Great Britain competent authority may charge fees for work carried out within the scope of Regulation 1107/2009 which relates to evaluating applications made to it for the approval of active substances, safeners, synergists or basic substances, and such fees are payable in accordance with paragraph 2 of Schedule 1.
(1B) The Northern Ireland competent authority may charge fees for work carried out within the scope of Regulation 1107/2009 which relates to evaluating parallel trade applications made to it and such fees are payable in accordance with paragraph 1A of Schedule 1.”;
(c)in paragraph 2—
(i)for “United Kingdom” substitute “Great Britain”;
(ii)after “applications for import tolerances” insert “and standalone MRL applications”;
(d)after paragraph 2, insert—
“(2A) A Great Britain competent authority may charge fees for the evaluation of supplementary information provided in accordance with Article 14(3) of the MRL Regulation and such fees are payable in accordance with Schedule 3.”;
(e)in paragraph (4), for “a United Kingdom” substitute “the relevant”;
(f)in paragraph (5), for “A United Kingdom” substitute “The relevant”;
(g)in paragraph (7), for “a United Kingdom” substitute “the relevant”.]
Textual Amendments
F1Sch. 1 para. 10 substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 7
Commencement Information
I1Sch. 1 para. 10 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1(2)